Literature DB >> 8837395

Serum antibody reactivity to recombinant mig and whole cell antigens in Mycobacterium avium infection.

G Plum1, M Brenden, P Santos, E Schwarz, U Wahnschaffe, G Mauff, G Pulverer.   

Abstract

Mycobacterium avium is a significant opportunistic pathogen in immunocompromised patients. Moreover, the prevalence of infections in patients without known predisposing conditions has also been increasing in recent years. Patients would greatly benefit from early diagnosis of disseminated infection. Serodiagnostic tests have already been promising in tuberculosis and immunocompetent patients but studies in HIV-infected patients and humoral response to M. avium antigens resulted in conflicting data. We have evaluated the use of the phagocytosis-induced MIG protein of M. avium as a diagnostic antigen. Serum antibody levels of M. avium-infected, HIV-negative patients were significantly elevated for the recombinant MIG (p < 0.001) and also for M. avium whole-cell antigens (p < 0.025) as compared to controls. In contrast, HIV-infected patients with disseminated M. avium infection demonstrated also elevated levels of antibody for the whole-cell antigen (p < 0.00001) but a decreased reactivity for the MIG antigen (p < 0.007). The recombinant antigen proved to have no cross-reactivity with M. tuberculosis antigens as antibody levels were decreased in tuberculosis patients (p < 0.001). Therefore, a simultaneous serological test using recombinant MIG and the whole cell antigens might be helpful in the sometimes problematic diagnosis of M. avium infections in patients without predisposing conditions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8837395     DOI: 10.1016/s0934-8840(96)80110-1

Source DB:  PubMed          Journal:  Zentralbl Bakteriol        ISSN: 0934-8840


  1 in total

1.  The potential of recombinant antigens ESAT-6, MPT63 and mig for specific discrimination of Mycobacterium tuberculosis and M. avium infection.

Authors:  Claudia Rolinck-Werninghaus; Klaus Magdorf; Klaus Stark; Konstantin Lyashchenko; Maria Laura Gennaro; Roberto Colangeli; T Mark Doherty; Peter Andersen; Georg Plum; Udo Herz; Harald Renz; Ulrich Wahn
Journal:  Eur J Pediatr       Date:  2003-04-25       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.